GGrantIndex
Sort

326,823 grants matching clinical trial

CoVPN 3005: Efficacy, Immunogenicity, and Safety of Two SARS-CoV-2 Recombinant Protein Vaccines with Adjuvant in Adults 18 Years of Age and Older - LC 3

$3,544,100
Margaret Juliana McElrath · Fred Hutchinson Cancer Center · UM1 · FY2022 · AI

Childhood Cancer Survivor Study

$3,543,250
Gregory Armstrong · St. Jude Children'S Research Hospital · U24 · FY2021 · CA

The AYA-RISE Intervention: Risk Information and Screening Education for Adolescents and Young Adults with Cancer Predisposition Syndromes

$3,543,148
Jennifer W Mack · Dana-Farber Cancer Inst · U01 · FY2019 · CA

Development of rationally designed HIV vaccines

$3,542,953
Genoveffa Franchini · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA

Addressing the chronic pain epidemic among older adults in underserved community center; The GetActive+ study.

$3,542,451
Ana-Maria Vranceanu · Massachusetts General Hospital · R33 · FY2024 · AG

Development of a recombinant trimeric RSV-F vaccine (DS-Cav1)

$3,542,377
Frank Arnold · National Institute Of Allergy And Infectious Diseases · ZIA · FY2018 · AI

Utah Center for Clinical and Translational Science

$3,542,367
Rachel Hess · University Of Utah · UL1 · FY2019 · TR

COG NCTN Network Group Operations Center - Year 10 Administrative Supplements

$3,541,929
Douglas S. Hawkins · Public Health Institute · U10 · FY2023 · CA

Boston HIV CTU

$3,541,665
Daniel R Kuritzkes · Brigham And Women'S Hospital · UM1 · FY2024 · AI

Cancer Center Support Grant P30

$3,540,688
Primo N Lara · University Of California At Davis · P30 · FY2022 · CA

Improving Clinical trial Education, Recruitment, and Enrollment at CTSA Hubs (I-CERCH)

$3,539,629
Paul A. Harris · Vanderbilt University Medical Center · U24 · FY2018 · TR

Novel, Non-Opioid, Non-Addictive Intrathecal Therapy for the Treatment of Chronic Pain

$3,539,507
James N Campbell · Centrexion Therapeutics Corporation · UH3 · FY2024 · NS

Utah Trial Innovation Center

$3,539,199
Jonathan Michael Dean · University Of Utah · U24 · FY2018 · TR

THERAPY OF CML

$3,538,057
University Of Texas Md Anderson Can Ctr · P01 · FY2005 · CA

CONCERT-Clinical Effectiveness Research (CONCERT-CER)

$3,537,987
Edward T Naureckas · University Of Chicago · RC2 · FY2010 · HL

DCTD Cancer Imaging

$3,537,972
David Heimbrook · Leidos Biomedical Research, Inc. · N01 · FY2014 · CA

Coordinating Center for Organ Transplant Clinical Trials (U01)

$3,537,949
David N. Ikle · Rho Federal Systems Division, Inc. · U01 · FY2010 · AI

WISDOM: A platform to optimize subtype-specific screening and prevention

$3,537,456
Laura J Esserman · University Of California, San Francisco · P01 · FY2024 · CA

Biology of Long-Term Mechanical Circulatory Support

$3,537,329
Columbia University Health Sciences · P50 · FY2005 · HL

The Therapy of CML

$3,537,028
Richard E. Champlin · University Of Tx Md Anderson Can Ctr · P01 · FY2012 · CA

Epidemiology of Diabetes Interventions and Complications Data Coordinating Center

$3,535,377
John M Lachin · George Washington University · U01 · FY2012 · DK

Molecular and Clinical Manifestations of Matrix and Aggregate Myopathies

$3,535,200
Carsten Bonnemann · National Institute Of Neurological Disorders And Stroke · ZIA · FY2018 · NS

RCT OF PLANT-BASED DIET IN BREAST CANCER RECURRENCE

$3,535,076
University Of California San Diego · R01 · FY2004 · CA

NATIENS: A Phase III Randomized Double Blinded Study to Determine the Mechanisms and Optimal Management of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis

$3,535,017
Elizabeth Phillips · Vanderbilt University Medical Center · U01 · FY2021 · AI

Pterygopalatine Fossa (PPF) Block as an Opioid Sparing Treatment for AcuteHeadache in Aneurysmal Subarachnold Hemorrhage

$3,534,431
Katharina Maria Busl · University Of Florida · U01 · FY2024 · NS